Factors related to glucose-lowering efficacy of oral antidiabetics:a systematic review and meta-analysis focusing on ethnicity and study regions by 永木(藤田) 華世
  
Factors related to glucose-lowering efficacy of oral 
antidiabetics: a systematic review and meta-analysis 
focusing on ethnicity and study regions 
 
 
 
 
Kayo Nagaki (Fujita) 
 
 
Department of Clinical Medicine (Pharmaceutical Medicine) 
Kitasato University Graduate School of Pharmaceutical Sciences 
 
 
 
5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan 
 
 
Abstract 
 Type 2 diabetes is a group of metabolic diseases characterized by 
hyperglycemia resulting from lack of insulin action. The mechanism for a lack of 
insulin action has two components: impaired insulin secretion and decreased insulin 
sensitivity (insulin resistance) in organs on which insulin acts. Both are components of 
the pathogenesis of type 2 diabetes. In general, insulin resistance plays a key role 
causing type 2 diabetes in Caucasians, whereas impaired insulin secretion plays a key 
role in the development of type 2 diabetes in East Asians. 
 Several systematic reviews and meta-analyses have been conducted including 
an analysis to investigate the difference between ethnic groups in glucose lowering 
efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. However, no consistent result has 
been found to date. Thus, in this first research, we performed a systematic review and 
meta-analysis of randomized controlled studies and conducted meta-regression analyses 
to assess the correlation between the glucose-lowering efficacy of DPP-4 inhibitors in 
patients with type 2 diabetes and potential factors including ethnicity of study subjects 
and study regions; in particular, Japanese were dealt separately from other Asians. The 
finding of the first research suggested that a higher baseline Hemoglobin A1c (HbA1c), 
studies in Japanese subjects, and studies conducted in Japan are factors of greater 
efficacy of DPP-4 inhibitors on weighted mean difference (WMD) in the change of 
HbA1c from baseline. 
 As for the sodium glucose co-transporter-2 (SGLT-2) inhibitor, systematic 
reviews and meta-analysis to investigate the difference in efficacy and safety of SGLT-2 
inhibitors between different ethnic groups considering the pathophysiology has not been 
conducted so far. The reason might be its insulin independent mechanism of action. 
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Thus, as a secondary research, we performed a systematic review and meta-analysis of 
randomized controlled studies and conducted meta-regression analyses to assess the 
correlation between the glucose-lowering efficacy of SGLT-2 inhibitors in patients with 
type 2 diabetes and potential factors including ethnicity of study subjects and study 
regions. The finding of the second research suggested that higher fasting plasma glucose 
is a factor of greater efficacy of SGLT-2 inhibitors on WMD in the change of HbA1c 
from baseline. 
 Our finding suggests that paying attention to baseline HbA1c for DPP-4 
inhibitors and baseline fasting plasma glucose for SGLT-2 inhibitors in planning and 
conducting clinical studies, and in comparing the data with other clinical studies is 
important. With regards to the ethnicity of study subjects, our finding indicates that 
differences in the contribution of the insulin secretory defect and the insulin resistance 
in the pathophysiology of type 2 diabetes between Asians and non-Asians do not affect 
the response to active oral hypoglycemic agents which have insulin independent 
mechanism. 
 In type 2 diabetes area, placebo effect has rarely been discussed. The third 
research focus, therefore, was to identify the factors that contribute to placebo effect in 
clinical studies for both DPP-4 inhibitor and SGLT-2 inhibitor by meta-regression 
analyses. The finding of the third research suggested that study conduct in Asia is a 
factor of larger HbA1c change from baseline in the placebo group. This differential 
HbA1c response in the placebo arm should be taken into consideration when comparing 
the data based on different clinical practice in each region. In the future, it is desirable to 
evaluate the influence of different study regions and/or subject ethnicity on efficacy and 
safety in multiregional studies. 
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1. Introduction 
 Type 2 diabetes is a group of metabolic diseases characterized by 
hyperglycemia resulting from lack of insulin action. The chronic hyperglycemia of 
diabetes is associated with long-term damage, dysfunction, and failure of various organs, 
especially the eyes, kidneys, nerves, heart, and blood vessels 
The prevalence of diabetes has recently been increasing worldwide [1-3]. The 
number of adults with diabetes was estimated to be 415 million in 2015 and is expected 
to rise to 642 million by 2040 [3]. East Asian countries have also seen a continuous 
increase in diabetes [2,3]. According to a 1997 survey in Japan [4], total of “individuals 
strongly suspected of having diabetes” and “individuals in whom diabetes cannot be 
ruled out” were approximately 13.7 million, which increased to 20.5 million in 2012 
[5]. 
 The mechanism for a lack of insulin action has two components: impaired 
insulin secretion and decreased insulin sensitivity (insulin resistance) in organs on 
which insulin acts [6]. Impaired insulin secretion is a condition in which enough insulin 
is not supplied to satisfy the adequate action on the organs. Insulin resistance refers to a 
condition in which the normal function of insulin in peripheral tissues does not occur. 
Both are components of the pathogenesis of type 2 diabetes. In general, insulin 
resistance plays a key role causing type 2 diabetes in Caucasians [7], whereas impaired 
insulin secretion plays the key role in the development of type 2 diabetes in East Asians 
[8-11]. Besides the differences in pathogenesis between ethnic groups, there are also 
differences at the individual level. In the case of impaired insulin secretion, excessive 
lipid uptake occurs even in mild obesity, and when a lifestyle that is deficient in exercise 
is superimposed on this, insulin resistance, and thus type 2 diabetes, is more likely to 
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occur. 
 In controlling type 2 diabetes, lifestyle management focusing on diet and 
exercise is carried out first, and in case the target value for glycemic control is not 
achieved, drug treatment is started. Seven oral hypoglycemic agents are divided into 
three modes of actions: insulin sensitizing agents, insulin secretagogues, and 
carbohydrate absorption/ excretion-modulating agent. Biguanides and thiazolidines are 
classified as insulin sensitizing agents, sulfonylureas, fast-acting insulin secretagogues 
and dipeptidyl peptidase-4 (DPP-4) inhibitors are insulin secretagogues, and 
α-glucosidase inhibitor and sodium glucose co-transporter-2 (SGLT-2) inhibitors are 
carbohydrate absorption/excretion-modulating agents. Pharmacotherapy will be selected 
depending on the patient’s etiology and patho-physiological stages (states) considering 
different modes of actions of each drug. 
 There is no apparent difference among the regions e.g., the United States, 
European countries, and Japan, regarding diagnosis and drug treatment options for type 
2 diabetes. Hemoglobin A1c (HbA1c) is widely used internationally as an important 
index in the treatment of diabetes and a primary endpoint of efficacy in clinical studies. 
Based on the background such as the differences in pathogenesis and so on, however, it 
has been considered in Japan that extrapolation of multinational clinical study results by 
bridging strategy and/or conducting multinational studies is difficult in the development 
of an oral hypoglycemic agent for type 2 diabetes patients. 
 Several systematic reviews and meta-analyses have been conducted so far 
including an analysis to investigate the difference between ethnic groups in glucose 
lowering efficacy of DPP-4 inhibitors. Kim et al. [15] reported improved glucose 
lowering efficacy in Asians compared with other ethnic groups, and Park et al. [16] 
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reported the difference between Japanese and non-Japanese patients in efficacy and 
safety. However there were several limitations in these analyses. First, the number of 
articles which deal with clinical studies in the Asian or Japanese population is few 
compared to that in the Western population. Second, seven Japanese studies referred in 
the above mentioned articles showed a greater reduction in HbA1c such as –1.67%, 
which is far greater than the generally recognized value such as –0.6 % to –0.9 %. Third, 
HbA1c as it had been expressed in Japan used the Japan Diabetes Society (JDS) system 
values and not the National Glycohemoglobin Standardization Program (NGSP) values. 
From April 1, 2013, the HbA1c results are reported using only the NGSP values and 
there is a possibility that meta-analysis in the above mentioned articles were conducted 
in different HbA1c values. 
 As for the SGLT-2 inhibitor, which appeared on the market most recently, a 
pooled analysis was conducted to assess the efficacy and safety in patients of different 
ethnicities, Hispanic/Latino and non-Hispanic/Latino [17]. But systematic reviews and 
meta-analysis to investigate the difference in efficacy and safety of SGLT-2 inhibitors 
between different ethnic groups considering the pathophysiology such as Asian and 
non-Asian or Japanese and non-Japanese like DPP-4 inhibitor has not been conducted 
so far. The reason might be its insulin independent mechanism of action. 
 The placebo phenomenon in chronic pain or neuropsychiatric disorder has been 
widely recognized in clinical research because high placebo responses were reported to 
be the cause of failure of clinical studies. In type 2 diabetes area, however, placebo 
effect has rarely been discussed. 
 Against this background, we performed a systematic review and meta-analysis 
of randomized controlled studies for type 2 diabetes and assessed the correlation 
3 
 
between the glucose-lowering efficacy of oral hypoglycemic agents and potential 
factors related to clinical study design and subject demographic, and conduct including 
the ethnicity of study subjects and study regions. As oral hypoglycemic agents, we 
selected two classes of mechanism of actions, a DPP-4 inhibitor, which has an insulin 
secretion mechanism (Research 1), and a SGLT-2 inhibitor, which has an insulin 
independent mechanism (Research 2). Additionally, we conducted an analysis to 
identify factors contributing to placebo effect in clinical studies for type 2 diabetes. 
Based on these analyses, we discuss the points to be considered in future clinical 
development of oral hypoglycemic drugs. 
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2. Research 1 (DPP-4 inhibitor) 
2.1. Objectives 
 DPP-4 inhibitors are a class of oral hypoglycemic agents that inhibit the 
enzyme DPP-4. The enzyme breaks down the incretin gastrointestinal hormones 
glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, which are 
released in response to a meal and stimulate glucose-dependent insulin secretion [12, 
13]. DPP-4 inhibitors are now in widespread use in clinical practice including East 
Asian countries and are rapidly becoming first-line therapy [14]. 
 The pathophysiological differences may have an impact on the therapeutic 
approach and several systematic reviews and meta-analyses have been conducted 
including an analysis to investigate the difference between ethnic groups in glucose 
lowering efficacy of DPP-4 inhibitors. Kim et al. [15] reported improved glucose 
lowering efficacy in Asians compared with other ethnic groups, and Park et al. [16] 
reported the difference between Japanese and non-Japanese patients in efficacy and 
safety. Others [18-20] have analyzed the correlation between glucose-lowering efficacy 
and baseline characteristics without including ethnic information. However, no 
consistent result has been found to date.  
 Thus, we performed a systematic review and meta-analysis of randomized 
controlled studies and conducted meta-regression analyses to assess the correlation 
between the glucose-lowering efficacy of DPP-4 inhibitors including alogliptin, 
linagliptin, sitagliptin, saxagliptin and vildagliptin in patients with type 2 diabetes and 
potential factors including ethnicity of study subjects and study regions; in particular, 
Japanese were dealt separately from other Asians. 
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2.2. Method 
 The study conduct and results were reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [21]. 
 
2.2.1. Data sources and searches 
 A systematic search was performed to identify potentially relevant studies in 
Medline, Embase, Cochrane Central Register, Japan Medical Abstracts Society and 
ClinicalTrials.gov databases up to October 4, 2016. In addition, the search included the 
reviews of approved drugs from the US Food and Drug Administration (www.fda.gov), 
European Medicines Agency (www.ema.europa.eu) and Japanese Pharmaceuticals and 
Medical Devices Agency (www.pmda.go.jp). An extensive search for alogliptin, 
linagliptin, sitagliptin, saxagliptin and vildagliptin was performed. 
 Eligibility criteria for study selection included the following: (1) randomized 
controlled studies comparing a DPP-4 inhibitor with a placebo as either monotherapy or 
combination therapy with other oral glucose-lowering drugs in patients with type 2 
diabetes, (2) studies with treatment duration of at least 12 weeks, (3) studies with 
information on HbA1c values of placebo-adjusted change from baseline, and (4) studies 
published or described in English or Japanese. Eligibility was assessed independently 
by two authors (K.F. and M.K.), and disagreements were resolved by consensus with 
another author (M.N.). 
 Exclusion criteria included the following: (1) studies with duration of less than 
12 weeks because of inadequate time to assess HbA1c change, (2) duplicate and 
extended studies from original studies, and (3) studies lacking relevant information. 
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2.2.2. Data extraction 
 Two authors (K.F. and M.K.) independently conducted data extraction. Any 
disagreements were resolved by consensus with another author (M.N.). The following 
data were extracted from the eligible studies: study design (monotherapy or oral 
combination therapy), name of the first author, year of publication, country where the 
study was conducted, treatment regimen, study duration, number of participants, 
percentage of male, means of age, duration of diabetes, baseline HbA1c values, baseline 
fasting plasma glucose, baseline body mass index (BMI), baseline body weight, and 
percentages of Asians and Japanese subjects. The primary outcome was the effect of 
DPP-4 inhibitors on HbA1c change from baseline compared with placebo at each 
study’s primary endpoint. 
 For dose-ranging studies, only data from currently approved medication doses 
were extracted. In the absence of such data, equivalent amounts of daily doses were 
used. If a study had two or three comparisons (one monotherapy arm and one or two 
combination therapy arms), each comparison was treated separately. When there was a 
comparison for different administration times in a day (morning vs. evening), both data 
were used. Some data not available in the original paper were subsequently extracted 
using information from a full report available in the study registry, ClinicalTrials.gov, or 
from reviews of approved drugs by regulatory agencies. 
 For ethnicity information, we followed the classification of ‘Asian’ used by the 
authors of each study. If a study did not disclose ethnic information but was conducted 
in Asian countries with a relatively homogeneous population, e.g., Korea, China, Japan 
or Taiwan, we assumed the study participants were Asian. In addition, if a study did not 
disclose ethnic information but was conducted only in Japan, we assumed the study 
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participants were Japanese. 
 In order to further explore potential differences in HbA1c-lowering efficacy 
among the ethnicity and study regions, we created three classifications, Type A, B and C. 
Type A and Type B focused on ethnicity of study subjects, and Type C focused on study 
regions. In Type A classification, Japanese was included in Asian, and we categorized 
the studies either as a “study in Asian subjects” or a “study in non-Asian subjects” based 
on whether the percentage of Asians was larger than or equal to 50% or not. In Type B, 
Japanese was dealt separately from Asian, and we divided the studies into three groups: 
a “study in Japanese subjects” that enrolled only Japanese, a “study in Asian subjects” 
that excluded the study in Japanese subjects from study in Asian subjects of Type A, and 
a “study in non-Asian subjects.” In Type C, we divided the studies into three groups: a 
“study conducted in Japan” that conducted only in Japan, an “study conducted in Asia” 
conducted only in Asia and excluding those conducted only in Japan, and a “study 
conducted multinationally.” 
 For HbA1c value, when the Japan Diabetes Society (JDS) values, HbA1c 
(JDS), were used in Japanese studies [22], then they were calculated into National 
Glycohemoglobin Standardization Program (NGSP) equivalent value (%) using the 
formula HbA1c (%) = HbA1c (JDS) (%) + 0.4% and used in the present study. 
 
2.2.3. Study quality and risk of bias assessment 
 The Jadad Scale was adopted to assess the quality of all included studies. We 
evaluated the included studies regarding randomization, concealment of allocation, 
double-blinding, withdrawals and dropouts. To assess publication bias, we used the 
funnel plot and Egger’s test. 
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2.2.4. Statistical analysis 
 Weighted mean difference (WMD) and 95% confidence interval for HbA1c 
change from baseline in DPP-4 inhibitors compared with placebo was calculated. 
Heterogeneity between studies was assessed by using Q statistic and I2 statistic. A 
P-value of Q statistic <0.10 and a value of 50% or greater of I2 statistic was considered 
significant. A random-effect model was used because significant heterogeneity was 
reported in several meta-analyses [15,16]. Meta-regression was applied to investigate 
potential factors affecting the placebo adjusted HbA1c lowering efficacy. The 
pre-specified factors such as study duration, percentage of male, age, duration of 
diabetes, baseline HbA1c values, fasting plasma glucose, BMI, body weight, percentage 
of Asians and additional categorizations regarding ethnicity of study subjects and study 
regions were used in the meta-regression. 
 Univariate meta-regression was performed first to identify potential factors 
affecting the HbA1c-lowering efficacy of the DPP-4 inhibitor. Negative coefficient 
indicates efficacy is in favor of the factor. A significant association was defined as P 
<0.2 in univariate meta-regression. Factors were further analyzed by multivariate 
meta-regression. When correlation between explanatory variables was identified, one 
variable was selected to be included in the multivariate meta-regression. A statistically 
significant difference was defined as P <0.05 in the multivariate meta-regression. 
Analyses were performed using StatDirect version 2.7.9 (StatDirect Ltd., Altrincham, 
Cheshire, UK) and R software, version 3.2.0 [23]. 
 
2.3. Result 
2.3.1. Literature search 
 We identified 2,721 potentially relevant articles from a literature search. Based 
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on the review of the abstracts, 72 studies met all of the inclusion criteria. Further 270 
studies were identified in the ClinicalTrials.gov registry and among them 7 unpublished 
clinical studies were included in the analysis (Fig. 1). A total of 79 studies (Appendix: 
reference 1-79) with 91 arms and 25,095 patients were used for the analysis (Table 1). 
Regarding the factors related to ethnicity and regions, in Type B, 17 were studies in 
Asian subjects, 18 were studies in Japanese subjects and 41 were studies in non-Asian 
subjects. As for Type C, 6 were studies conducted in Asia, 18 were studies conducted in 
Japan and 55 were studies conducted multinationally (Table 2). 
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Figure 1 Flow diagram of study selection 
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Table 1 Studies included in the analysis 
Source 
Number of 
participants 
Treatment 
duration 
(weeks) 
DPP-4 inhibitors 
background antidiabetic 
therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
DeFronzo, 20081 196 26 Alogliptin 25 mg QD none 53.4  8.0  
Nauck , 20092 314 26 Alogliptin 25 mg QD metformin 54.7  7.9  
Pratley, 20093 296 26 Alogliptin 25 mg QD pioglitazone 55.3  8.0  
Pratley, 20094 297 26 Alogliptin 25 mg QD glyburide 56.7  8.1  
Seino, 20115 155 12 Alogliptin 25 mg QD none 59.3  7.9  
Kaku, 20116 228 12 Alogliptin 25 mg QD pioglitazone 59.7  7.9  
Seino, 20117 154 12 Alogliptin 25 mg QD voglibose 62.6  8.0  
Seino, 20128 207 12 Alogliptin 25 mg QD glimepiride 60.0  8.6  
Seino, 20129 196 12 Alogliptin 25 mg QD metformin 52.2  8.0  
Pan, 201610_1a 185 16 Alogliptin 25 mg QD none 52.4  8.0 
Pan, 201610_2b 197 16 Alogliptin 25 mg QD metformin 53.1  8.0 
Pan, 201610_3c 124 16 Alogliptin 25 mg QD 
pioglitazone (with or without 
metformin) 
52.2  
8.0 
Forst, 201011 137 12 Linagliptin 5 mg QD metformin 59.9  8.4  
Del Prato, 201112 503 24 Linagliptin 5 mg QD none 55.7  8.0  
Taskinen, 201113 700 24 Linagliptin 5 mg QD metformin 56.5  8.1  
Owens, 201114 1055 24 Linagliptin 5 mg QD metformin and sulfonylurea 58.1  8.1  
Lewin, 201215 245 18 Linagliptin 5 mg QD sulfonylurea 56.9  8.6  
Kawamori, 201216 239 12 Linagliptin 5 mg QD none 60.1  8.0  
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Source 
Number of 
participants 
Treatment 
duration 
(weeks) 
DPP-4 inhibitors 
background antidiabetic 
therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
Ross, 201217_1a 268 12 Linagliptin 5 mg QD metformin 58.6  8.0  
Ross, 201217_2b 267 12 Linagliptin 2.5 mg BID metformin 58.9  8.0  
Haak, 201218 214 24 Linagliptin 5 mg QD none 56.0  8.7  
Barnett, 201219 227 18 Linagliptin 5 mg QD none 56.5  8.1  
Bajaj, 201420 278 24 Linagliptin 5 mg QD metformin and pioglitazone 53.8  8.4  
Chen, 201521 301 24 Linagliptin 5 mg QD none 54.4  8.0  
Wang, 201622 305 24 Linagliptin 5 mg QD metformin 55.6  8.0  
Rosenstock, 200823 114 12 Saxagliptin 5 mg QD none 54.6  8.0  
Rosenstock, 200924 201 24 Saxagliptin 5 mg QD none 53.9  8.0  
DeFronzo, 200925 370 24 Saxagliptin 5 mg QD metformin 54.7  8.1  
Hollander, 200926 370 24 Saxagliptin 5 mg QD thiazolidinedione 53.6  8.3  
Chacra, 200927 520 24 Saxagliptin 5 mg QD glyburide 55.0  8.4  
Yang, 201128 570 24 Saxagliptin 5 mg QD metformin 54.1  7.9  
Pan, 201229 568 24 Saxagliptin 5 mg QD none 51.4  8.2  
Frederich, 201230_1a 148 24 Saxagliptin 5 mg QD AM none 55.1  7.9  
Frederich, 201230_2b 146 24 Saxagliptin 5 mg QD PM none 55.3  7.9  
White, 201431 160 12 Saxagliptin 2.5 mg BID metformin 55.4  7.9  
Moses, 201432 257 24 Saxagliptin 5 mg QD metformin and sulfonylurea 57.0  8.3  
Seino, 201433_1a 168 12 Saxagliptin 5 mg QD none 58.6  8.5  
Seino, 201433_2b 187 24 Saxagliptin 5 mg QD none 57.9  8.0  
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Source 
Number of 
participants 
Treatment 
duration 
(weeks) 
DPP-4 inhibitors 
background antidiabetic 
therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
Matthaei、201534 315 24 Saxagliptin 5 mg QD dapagliflozin and metformin 54.6  7.9  
NCT0091887935 213 24 Saxagliptin 5 mg QD none 48.7  8.3  
Ristic, 200536 121 12 Vildagliptin 100 mg QD none 55.4  7.7  
Dejager, 200737_1a 317 24 Vildagliptin 100 mg QD none 52.9  8.4  
Dejager, 200737_2b 312 24 Vildagliptin 50 mg BID none 52.5  8.5  
Pi-Sunyer, 200738_1a 183 24 Vildagliptin 100 mg QD none 52.0  8.4  
Pi-Sunyer, 200738_2b 175 24 Vildagliptin 50 mg BID none 51.1  8.5  
Bosi, 200739 367 24 Vildagliptin 100 mg QD metformin 54.2  8.4  
Garber, 200740 316 24 Vildagliptin 100 mg QD pioglitazone 54.4  8.7  
Garber, 200841 345 24 Vildagliptin 100 mg QD glimepiride 58.0  8.5  
Kikuchi, 200942 148 12 Vildagliptin 50 mg BID none 59.6  7.8  
Kikuchi , 201043 202 12 Vildagliptin 50 mg BID glimepiride 59.7  8.3  
Kikuchi, 201044_1a 124 12 Vildagliptin 50 mg BID none 59.5  7.7  
Kikuchi, 201044_2b 118 12 Vildagliptin 100 mg QD none 61.1  7.7  
Pan, 201245 290 24 Vildagliptin 50 mg BID metformin 54.3  8.0  
Odawara, 201446 139 12 Vildagliptin 50 mg BID metformin 58.1  8.0  
Raz, 200647 315 18 Sitagliptin 100 mg QD none 54.8  8.0  
Aschner, 200648 491 24 Sitagliptin 100 mg QD none 53.9  8.0  
Charbonnel, 200649 701 24 Sitagliptin 100 mg QD metformin 54.5  8.0  
Rosenstock, 200650 353 24 Sitagliptin 100 mg QD pioglitazone 56.3  8.0  
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Source 
Number of 
participants 
Treatment 
duration 
(weeks) 
DPP-4 inhibitors 
background antidiabetic 
therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
Hanefeld, 200751_1a 221 12 Sitagliptin 100 mg QD none 55.9  7.7  
Hanefeld, 200751_2b 222 12 Sitagliptin 50 mg BID none 55.6  7.7  
Hanefeld, 200751_3c 223 12 Sitagliptin 50 mg QD none 55.9  7.6  
Goldstein, 200752 355 24 Sitagliptin 100 mg QD none 53.4  8.8  
Hermansen, 200753_1a 212 24 Sitagliptin 100 mg QD glimepiride 54.8  8.4  
Hermansen, 200753_2b 229 24 Sitagliptin 100 mg QD glimepiride and metformin 57.1  8.3  
Scott, 200754 249 12 Sitagliptin 50 mg BID none 55.2  7.9  
Raz, 200855 190 30 Sitagliptin 100 mg QD metformin 54.8  9.2  
Scott, 200856 186 18 Sitagliptin 100 mg QD metformin 55.2  7.8  
Nonaka, 200857 152 12 Sitagliptin 100 mg QD none 55.3  8.0  
Mohan, 200958 530 18 Sitagliptin 100 mg QD none 50.9  8.7  
Iwamoto, 201059_1a 143 12 Sitagliptin 100 mg QD none 59.3  8.1  
Iwamoto, 201059_2b 145 12 Sitagliptin 50 mg QD none 60.2  8.1  
Kashiwagi, 201160 134 12 Sitagliptin 50 mg QD pioglitazone 58.4  8.1  
Barzilai, 201161 206 24 
Sitagliptin 50 or 100 mg 
QD 
none 71.9  7.8  
Tajima, 201162 138 12 Sitagliptin 50 mg QD glimepiride 60.7  9.1  
Yang, 201263 395 24 Sitagliptin 100 mg QD metformin 54.6  8.5  
Nicolle, 201264 130 12 Sitagliptin 100 mg QD metformin 52.5  7.7  
Fonseca, 201365 313 26 Sitagliptin 100 mg QD metformin and pioglitazone 56.0  8.8  
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Source 
Number of 
participants 
Treatment 
duration 
(weeks) 
DPP-4 inhibitors 
background antidiabetic 
therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
Dobs, 201366 262 18 Sitagliptin 100 mg QD metformin and rosiglitazone 54.5  8.8  
Roden, 201367 451 24 Sitagliptin 100 mg QD none 55.0  7.9  
Lavalle-González, 
201368  
549 26 Sitagliptin 100 mg QD metformin 55.4  7.9  
Tajima, 201369 133 12 Sitagliptin 50 mg QD voglibose 60.5  7.9  
Kadowaki, 201370 149 12 Sitagliptin 50 mg QD metformin 58.4  7.9  
Amin, 201571 112 12 Sitagliptin 100 mg QD metformin 47.5  8.0  
Ji, 2016 72 247 24 Sitagliptin 100 mg QD none 52.7  8.9  
Moses, 201673 422 24 Sitagliptin 100 mg QD sulfonylurea and metformin 54.9  8.4  
NCT0117738474 381 24 Sitagliptin 100 mg QD acarbose 57.1  8.1  
NCT0128999075 451 52 Sitagliptin 100 mg QD none 55.0  7.9  
NCT0133887076 100 12 Sitagliptin 100 mg QD metformin 55.7  8.1  
NCT0133673877 107 12 Sitagliptin 100 mg QD metformin 56.7  8.3  
NCT0159077178 498 24 Sitagliptin 100 mg QD 
sulfonylurea with or without 
metformin 
57.0  8.6  
NCT0170322179 248 24 Sitagliptin 50 mg QD none 60.3  NR 
QD once-daily dosing, BID twice-daily dosing, NR not reported 
a 1 represents the first pair of the article 
b 2 represents the second pair of the article 
c 3 represents the third pair of the article 
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 Table 2 Three classifications for studies 
Type A Study in non-Asian subjects 
41 studies 
Study in Asian subjects 
35 studies 
 
Type B Study in non-Asian subjects 
41 studies 
Study in Asian subjects (excluding 
the Japanese) 
17 studies 
Study in Japanese subjects a 
18 studies 
Type C Study conducted multinationally 
55 studies 
Study conducted in Asia 
(excluding Japan) 
6 studies 
Study conducted in Japan a 
18 studies 
a Studies classified as "Study in Japanese subjects" (Type B) and "Study conducted in Japan" (Type C) were the same. 
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 2.3.2. Quality of included studies and publication bias 
 The Jaded score was 3.74, and we determined the quality of included studies 
was high. The funnel plot of WMD for HbA1c and standard error in 79 studies is shown 
in Fig. 2. Funnel plot asymmetry was assessed using Egger's test and it indicated that 
there was no publication bias (p = 0.067). The I2 statistic test for heterogeneity was 
69.7%, and the value of Q statistic was significant. 
 
 Figure 2 Funnel plot of weighted mean difference for HbA1c and standard error 
 
2.3.3. Primary outcome 
 HbA1c data for 91 arms from 79 studies were pooled. The difference of HbA1c 
between the DPP-4 inhibitor group and placebo group was −0.695% (95% CI −0.734 to 
−0.656). 
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2.3.4. Univariate meta-regression 
 Univariate meta-regression showed relations between the WMD in the change 
of HbA1c from baseline value and several factors such as study duration 
(coefficient=0.009, p = 0.001), percentage of male (−0.009, p <0.001), age (−0.024, p 
<0.001), duration of diabetes (−0.034, p =0.001), baseline HbA1c values (−0.087, p = 
0.162), BMI (0.029, p <0.001), body weight (0.009, p <0.001) and percentage of Asians 
(−0.002, p <0.001). Additionally, studies in Asian subjects in Type A (−0.129, p = 
0.001), studies in Japanese subjects in Type B (−0.254, p <0.001), and studies 
conducted in Japan in Type C (−0.263, p <0.001) showed relations in each of the 
analyses. Because BMI and body weight correlated with the percentage of Asians, we 
excluded BMI and body weight from the multivariate meta-regression, and used the 
three classifications (Type A, B and C). 
 
2.3.5. Multivariate meta-regression 
 The factors significantly associated with the WMD in the change of HbA1c 
from baseline using univariate meta-regression were further analyzed by multivariate 
meta-regression (Table 3). Baseline HbA1c was identified as a common influencing 
factor in all the analyses using the three types of classifications. Also, study in Japanese 
subjects in Type B and study conducted in Japan in Type C were identified as 
influencing factors. 
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Table 3 Results of multivariate meta-regression analysis 
 
 
 
Factors Estimate 95% CI P-value 
a. Multivariate meta-regression with Type A 
Study duration (week) 0.007 (-0.003, 0.016) 0.166 
Male (%) -0.003 (-0.010, 0.004) 0.392 
Age (years) -0.011 (-0.027, 0.004) 0.138 
Duration of diabetes (years) -0.012 (-0.034, 0.011) 0.302 
Baseline HbA1c (%) -0.169 (-0.300, -0.037) 0.012 
Study in Asian subjects -0.078 (-0.176, 0.019) 0.116 
b.  Multivariate meta-regression with Type B 
Study duration (week) 0.003 (-0.006, 0.013) 0.502 
Male (%) 0.001 (-0.006, 0.008) 0.684 
Age (years) -0.002 (-0.018, 0.013) 0.777 
Duration of diabetes (years) -0.007 (-0.029, 0.014) 0.499 
Baseline HbA1c (%) -0.157 (-0.281, -0.032) 0.014 
Study in Asian subjects 0.018 (-0.096, 0.132) 0.755 
Study in Japanese subjects - 0.242 (-0.389, -0.095) 0.001 
c.  Multivariate meta-regression with Type C 
Study duration (week) 0.003 (-0.007, 0.012) 0.588 
Male (%) 0.001 (-0.006, 0.008) 0.710 
Age (years) -0.004 (-0.019, 0.011) 0.605 
Duration of diabetes (years) -0.008 (-0.029, 0.014) 0.484 
Baseline HbA1c (%) -0.157 (-0.281, -0.032) 0.013 
Study conducted in Asia 0.011 (-0.129, 0.152) 0.873 
Study conducted in Japan - 0.243 (-0.391, -0.096) 0.001 
Type A, the studies were divided into 2 groups; a “study in Asian subjects” or a “study in non-Asian 
subjects” 
Type B, the studies were divided into 3 groups; a “study in Asian subjects”, a “study in Japanese 
subjects” or a “study in non-Asian subjects.” 
Type C, the studies were divided into three groups: a “study conducted in Asia”, a “study conducted 
in Japan” or a “study conducted multinationally.”  
HbA1c hemoglobin A1c 
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2.4. Discussion 
 We performed meta-regression analyses to identify the factors influencing the 
glucose-lowering efficacy of DPP-4 inhibitors by analyzing 79 studies with 91 arms and 
25,095 patients. We found WMD in the placebo-adjusted change of HbA1c from 
baseline was −0.695%, which is consistent with the previously reported meta-analyses 
ranging between −0.6% and −0.72%. 
 Using univariate meta-regression, factors such as study duration, percentage of 
male, age, duration of diabetes, baseline HbA1c values, BMI, body weight and 
percentage of Asians were identified to be correlated with WMD in the change of 
HbA1c from baseline. The results of study duration, percentage of male, age, duration 
of diabetes, BMI, and percentage of Asians were in agreement with the analysis 
conducted by Kim et al [15]. Additionally, in the present study, relations were shown in 
studies in Asian subjects in the classification Type A, studies in Japanese subjects in 
Type B and studies conducted in Japan in Type C. Based on these results, DPP-4 
inhibitors exhibit a better glucose-lowering efficacy with shorter study duration, in older 
patients, with longer duration of diabetes, with higher baseline HbA1c, with lower BMI 
and body weight, and with a higher percentage of Asians. A better glucose lowering 
efficacy was also shown in studies in Asian subjects, studies in Japanese subjects and 
studies conducted in Japan. 
 Multivariate meta-regression showed a better glucose lowering efficacy with 
high baseline HbA1c, suggesting baseline HbA1c is a robust factor. Moreover, studies 
in Japanese subjects in Type B and studies conducted in Japan in Type C were factors 
influencing the glucose-lowering efficacy of DPP-4 inhibitors. 
 Bloomgarden et al. [24] reported that the baseline glycemic status of patients 
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recruited into clinical studies strongly influences the reduction of HbA1c following 
pharmacologic intervention with the five major anti-hyperglycemic oral agent classes. 
The authors concluded that clinical investigators and study sponsors should consider 
these findings when testing the effectiveness of new anti-hyperglycemic agents. A 
higher baseline HbA1c would be a predictor of a greater HbA1c reduction with the use 
of DPP-4 inhibitors [20, 25]. However, the HbA1c value used by Esposito et al. [20] 
and Deacon [25] in their analysis was different from our study; they used the absolute 
HbA1c reduction without taking into account the placebo effect. In the present study, 
we found that a higher baseline HbA1c is a factor of greater efficacy of DPP-4 
inhibitors on WMD in the change of HbA1c from baseline. For clinical studies, the 
comparison with placebo is generally required. Therefore, in evaluating the efficacy of 
DPP-4 inhibitors in clinical development, it is important to provide the information on 
factors that influence the efficacy of DPP-4 inhibitors. Our finding suggests that paying 
attention to baseline HbA1c in planning and conducting of clinical studies, and 
comparing the data with other studies is important. 
 In the present study, we used three classifications regarding ethnicity of study 
subjects and study regions to explore potential differences among them. In the 
classification Type A, Japan was included in Asia. In Type B and C, we distinguished 
between Asia and Japan focusing on ethnicity in Type B and on regions in Type C. 
Studies in Japanese subjects and studies conducted in Japan are factors affecting the 
efficacy of DPP-4 inhibitors. However, studies in Asian subjects in Type B and studies 
conducted in Asia in Type C are not associated. This finding differs from those by Kim 
et al. [15], who reported that the DPP-4 inhibitors exhibit a better glucose-lowering 
efficacy in Asians than in other ethnic groups. Our finding indicates that differences in 
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the contribution of the insulin secretory defect and insulin resistance in the 
pathophysiology of type 2 diabetes between Asians and non-Asians does not 
significantly affect the response to DPP-4 inhibitors and does not explain the 
mechanism underlying the difference in the response. 
 The differences in the efficacy of DPP-4 inhibitors between Japanese and 
non-Japanese patients have been reported. Interestingly, Park et al. [16] suggested that 
the difference in characteristics such as age, duration of diabetes, baseline HbA1c and 
BMI between Japanese and non-Japanese patients could provide some explanation for 
the discrepancy in clinical studies. In their analysis, however, they did not clearly 
mention whether they took into consideration the difference of HbA1c values between 
JDS and NGSP. In our study, if an investigation in Japan did not mention the value of 
HbA1c (%), we checked the documents, review reports or other sources in order to use 
HbA1c (NGSP) equivalent values (%) for the analysis. The mean baseline HbA1c 
values were not significantly different among studies in non-Asian subjects, studies in 
Asian subjects and studies in Japanese subjects (data not shown), and the baseline 
HbA1c was an independent factor associated with the efficacy of DPP-4 inhibitors in 
our study.  
 When we looked at the placebo response in the classification Type B and Type 
C, the trend of the response was different among the three groups. Placebo response was 
increased in studies in Japanese subjects and studies conducted in Japan, whereas it 
decreased in studies in Asian subjects and studies conducted in Asia; in studies in 
non-Asian subjects and studies conducted multinationally it showed minimal change 
from baseline (data not shown). Further investigation is needed for better understanding 
the reason for the difference. In the present study, the factors analyzed in the univariate 
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meta-regression do not clearly explain the difference in efficacy of the DPP4-inhibitor 
in studies in Japanese subjects/studies conducted in Japan. 
 Our analysis indicates that studies in Japanese subjects /studies conducted in 
Japan as well as the baseline HbA1c values are associated with the efficacy of DPP-4 
inhibitors. This result should be taken into account when planning and conducting 
clinical studies. Further investigation is needed to understand the association of the 
differences in the contribution of insulin secretory defect and insulin resistance in the 
pathophysiology of type 2 diabetes among ethnicity with the glucose-lowering efficacy 
of DPP-4 inhibitors.  
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3. Research 2 (SGLT-2 inhibitor) 
3.1. Objectives 
 Most recently approved oral hypoglycemic drugs with a new mechanism is 
SGLT2 inhibitors. Inhibition of SGLT-2 decreases reabsorption of glucose in proximal 
renal tubular cells, leading to an increase in urinary glucose excretion and a reduction in 
plasma glucose levels. SGLT-2 inhibitors entered the Japanese market in 2014. 
Canagliflozin, dapagliflozin, and empagliflozin have been approved for use in the 
Unites States, the European Union and Japan, while ipragliflozin, luseogliflozin, and 
tofogliflozin have been approved for use only in Japan. 
 A pooled analysis was conducted to assess the efficacy and safety in patients of 
different ethnicities by Davidson et al. [17]. They reported that the SGLT2 inhibitor 
canagliflozin is equally effective and generally well-tolerated in both Hispanic/Latino 
and non-Hispanic/Latino. They focused on this ethnicity because Hispanic/Latino 
patients are one of the large populations with type 2 diabetes in the United States. But 
systematic reviews and meta-analysis to investigate the difference in efficacy and safety 
of SGLT-2 inhibitors between different ethnic groups considering the pathophysiology 
such as Asian and non-Asian or Japanese and non-Japanese like DPP-4 inhibitor has not 
been conducted so far. The reason might be its insulin independent mechanism of action, 
neither insulin secretion nor sensitization. 
 Thus, we performed a systematic review and meta-analysis of randomized 
controlled studies and conducted meta-regression analyses to assess the correlation 
between the glucose-lowering efficacy of SGLT-2 inhibitors including dapagliflozin, 
canagliflozin and empabliflozin in patients with type 2 diabetes and potential factors 
including ethnicity of study subjects and study regions; in particular, Japanese were 
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dealt separately from other Asians. 
 
3.2. Method 
 The study conduct and results were reported in accordance with the PRISMA 
statement [21]. 
 
3.2.1. Data sources and searches 
 A systematic search was performed to identify potentially relevant studies in 
Medline, Embase, Cochrane Central Register, Japan Medical Abstracts Society and 
ClinicalTrials.gov databases up to December 31, 2015. In addition, the search included 
the reviews of approved drugs from the US Food and Drug Administration 
(www.fda.gov), European Medicines Agency (www.ema.europa.eu) and Japanese 
Pharmaceuticals and Medical Devices Agency (www.pmda.go.jp). An extensive search 
for dapagliflozin, canagliflozin and empagliflozin was performed. 
 Eligibility criteria for study selection included the following: (1) randomized 
controlled studies comparing aSGLT-2 inhibitor with a placebo as either monotherapy 
or combination therapy with other oral glucose-lowering drugs in patients with type 2 
diabetes, (2) studies with treatment duration of at least 12 weeks, (3) studies with 
information on HbA1c values of placebo-adjusted change from baseline, and (4) studies 
published or described in English or Japanese. Eligibility was assessed independently 
by two authors (K.F. and M.K.), and disagreements were resolved by consensus with 
another author (M.N.). 
 Exclusion criteria included the following: (1) studies with duration of less than 
12 weeks because of inadequate time to assess HbA1c change, (2) duplicate and 
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extended studies from original studies, and (3) studies lacking relevant information. 
 
3.2.2. Data extraction 
 Two authors (K.F. and M.K.) independently conducted data extraction. Any 
disagreements were resolved by consensus with another author (M.N.). The following 
data were extracted from the eligible studies: study design (monotherapy or oral 
combination therapy), name of the first author, year of publication, country where the 
study was conducted, treatment regimen, study duration, number of participants, 
percentage of male, means of age, duration of diabetes, baseline HbA1c values, baseline 
fasting plasma glucose, BMI, baseline body weight, and percentages of Asians and 
Japanese subjects. The primary outcome was the effect of SGLT-2 inhibitors on HbA1c 
change from baseline compared with placebo at each study’s primary endpoint. 
 For dose-ranging studies, only data from currently approved medication doses 
were extracted. In the absence of such data, equivalent amounts of daily doses were 
used. If a study had two or three comparisons (one monotherapy arm and one or two 
combination therapy arms), each comparison was treated separately. When there was a 
comparison for different administration times in a day (morning vs. evening), both data 
were used. Some data not available in the original paper were subsequently extracted 
using information from a full report available in the study registry, ClinicalTrials.gov, or 
from reviews of approved drugs by regulatory agencies. 
 For ethnicity information, we followed the classification of ‘Asian’ used by the 
authors of each study. If a study did not disclose ethnic information but was conducted 
in Asian countries with a relatively homogeneous population, e.g., Korea, China, Japan 
or Taiwan, we assumed the study participants were Asian. In addition, if a study did not 
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disclose ethnic information but was conducted only in Japan, we assumed the study 
participants were Japanese. 
 In order to further explore potential differences in HbA1c-lowering efficacy 
among the ethnicity and study regions, we created three classifications, Type A, B and C. 
Type A and Type B focused on ethnicity of study subjects, and Type C focused on study 
regions. In Type A classification, Japanese was included in Asian, and we categorized 
the studies either as a “study in Asian subjects” or a “study in non-Asian subjects” based 
on whether the percentage of Asians was larger than or equal to 50% or not. In Type B, 
Japanese was dealt separately from Asian, and we divided the studies into three groups: 
a “study in Japanese subjects” that enrolled only Japanese, a “study in Asian subjects” 
that excluded the study in Japanese subjects from study in Asian subjects of Type A, and 
a “study in non-Asian subjects.” In Type C, we divided the studies into three groups: a 
“study conducted in Japan” that conducted only in Japan, an “study conducted in Asia” 
conducted only in Asia and excluding those conducted only in Japan, and a “study 
conducted multinationally.” 
 For HbA1c value, when the JDS values, HbA1c (JDS), were used in Japanese 
studies [22], then they were calculated into NGSP equivalent value (%) using the 
formula HbA1c (%) = HbA1c (JDS) (%) + 0.4% and used in the present study. 
 
3.2.3. Study quality and risk of bias assessment 
 The Jadad Scale was adopted to assess the quality of all included studies. We 
evaluated the included studies regarding randomization, concealment of allocation, 
double-blinding, withdrawals and dropouts. To assess publication bias, we used the 
funnel plot and Egger’s test. 
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 3.2.4. Statistical analysis 
 WMD and 95% confidence interval for HbA1c change from baseline in 
SGLT-2 inhibitors compared with placebo was calculated. Heterogeneity between 
studies was assessed by using Q statistic and I2 statistic. A P-value of Q statistic <0.10 
and a value of 50% or greater of I2 statistic was considered significant. A random-effect 
model was used because significant heterogeneity was reported in several meta-analyses 
[26, 27]. Meta-regression was applied to investigate potential factors affecting the 
placebo adjusted HbA1c lowering efficacy. The pre-specified factors such as study 
duration, percentage of male, age, duration of diabetes, baseline HbA1c values, fasting 
plasma glucose, BMI, body weight, percentage of Asians and additional categorizations 
regarding ethnicity of study subjects and study regions were used in the 
meta-regression. 
 Univariate meta-regression was performed first to identify potential factors 
affecting the HbA1c-lowering efficacy of the SGLT-2 inhibitor. Negative coefficient 
indicates efficacy is in favor of the factor. A significant association was defined as P 
<0.2 in univariate meta-regression. Factors were further analyzed by multivariate 
meta-regression. When correlation between explanatory variables was identified, one 
variable was selected to be included in the multivariate meta-regression. A statistically 
significant difference was defined as P <0.05 in the multivariate meta-regression. 
Analyses were performed using StatDirect version 2.7.9 (StatDirect Ltd., Altrincham, 
Cheshire, UK) and R software, version 3.2.0 [23]. 
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3.3. Result 
3.3.1. Literature search 
 We identified 496 potentially relevant articles from a literature search. Based 
on the review of the abstracts, 29 studies met all of the inclusion criteria. Further 83 
studies were identified in the ClinicalTrials.gov registry and among them 1 unpublished 
clinical study was included in the analysis (Fig. 3). A total of 30 studies (Appendix 2: 
1-33) with 75 arms and 20,170 patients were used for the analysis (Table 4). Regarding 
the factors related to ethnicity and regions, in Type B, 6 were studies in Asian subjects, 
5 were studies in Japanese subjects and 20 were studies in non-Asian subjects. As for 
Type C, 2 were studies conducted in Asia, 5 were studies conducted in Japan and 24 
were studies conducted multinationally (Table 5). 
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Figure 3 Flow diagram of study selection 
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Table 4 Studies included in the analysis 
Source 
Number of 
participant
s 
Treatment 
duration 
(weeks) 
SGLT-2 inhibitors background antidiabetic therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
BL FPG 
(mg/dl) 
List, 20091 112 12 Dapagliflozin 5 mg QD none 54.0  8.0  151.6  
List, 20091 101 12 Dapagliflozin 10 mg QD none 53.5  8.0  149.1  
Bailey, 20102 274 24 Dapagliflozin 5 mg QD metformin 54.0  8.1  167.2  
Bailey, 20102 272 24 Dapagliflozin 10 mg QD metformin 53.2  8.0  160.7  
Ferrannini, 20103_1a 139 24 Dapagliflozin 5 mg QD 
AM 
none 52.7  7.9  161.0  
Ferrannini, 20103_1a 145 24 Dapagliflozin 10 mg QD 
AM 
none 51.7  7.9  163.1  
Ferrannini, 20103_2b 135 24 Dapagliflozin 5 mg QD 
PM 
none 53.6  7.8  158.4  
Ferrannini, 20103_2b 143 24 Dapagliflozin 10 mg QD 
PM 
none 51.6  7.9  164.3  
Strojek, 20114 287 24 Dapagliflozin 5 mg QD glimepiride 60.3  8.1  173.3  
Strojek, 20114 296 24 Dapagliflozin 10 mg QD glimepiride 59.6  8.1  172.2  
Biley, 20125 136 24 Dapagliflozin 5 mg QD none 52.4  7.9  159.2  
Rosenstock, 20126 280 24 Dapagliflozin 5 mg QD pioglitazone 53.3  8.4  164.7  
Rosenstock, 20126 279 24 Dapagliflozin 10 mg QD pioglitazone 53.7  8.4  162.8  
Kaku, 20137 112 12 Dapagliflozin 5 mg QD none 58.2  8.1  161.8  
Kaku, 20137 106 12 Dapagliflozin 10 mg QD none 57.5  8.2  161.1  
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Source 
Number of 
participant
s 
Treatment 
duration 
(weeks) 
SGLT-2 inhibitors background antidiabetic therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
BL FPG 
(mg/dl) 
Jabbour, 20148 221 24 Dapagliflozin 10 mg QD sitagliptin 53.0  8.1  159.4  
Jabbour, 20148 226 24 Dapagliflozin 10 mg QD sitagliptin and metformin 56.7  7.9  165.8  
Kaku, 20149 173 24 Dapagliflozin 5 mg QD none 59.5  7.5  138.6  
Kaku, 20149 175 24 Dapagliflozin 10 mg QD none 58.9  7.5  139.2  
Ji, 201410 260 24 Dapagliflozin 5 mg QD none 51.4  8.3  160.8  
Ji, 201410 265 24 Dapagliflozin 10 mg QD none 50.6  8.3  164.7  
Matthaei, 201511 218 24 Dapagliflozin 10 mg QD sulfonylurea and metformin 61.0  8.2  173.8  
Schumm-Draeger, 
201512 
201 16 Dapagliflozin 2.5 mg BID metformin 58.4  7.9  155.4  
Schumm-Draeger, 
201512 
200 16 Dapagliflozin 5 mg BID metformin 56.9  7.9  156.4  
NCT0073687913 136 24 Dapagliflozin 5 mg QD none 52.4  7.9  159.2  
Rosenstock, 201214 129 12 Canagliflozin 100 mg QD metformin 52.5  7.8  166.0  
Rosenstock, 201214 130 12 Canagliflozin 200 mg QD metformin 53.1  7.7  162.0  
Rosenstock, 201214 129 12 Canagliflozin 300 mg QD metformin 52.8  7.7  161.5  
Wilding, 201315 313 26 Canagliflozin 100 mg QD sulfonylurea and metformin 57.1  8.1  171.0  
Wilding, 201315 312 26 Canagliflozin 300 mg QD sulfonylurea and metformin 56.5  8.1  168.3  
Inagaki, 201316 149 12 Canagliflozin 100 mg QD none 57.7  8.0  165.9  
Inagaki, 201316 151 12 Canagliflozin 200 mg QD none 57.3  8.1  168.3  
Inagaki, 201316 150 12 Canagliflozin 300 mg QD none 57.4  8.1  169.9  
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Source 
Number of 
participant
s 
Treatment 
duration 
(weeks) 
SGLT-2 inhibitors background antidiabetic therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
BL FPG 
(mg/dl) 
Lavalle-Gonzalez, 
201317 
551 26 Canagliflozin 100 mg QD metformin 55.4  7.9  166.2  
Lavalle-Gonzalez, 
201317 
550 26 Canagliflozin 300 mg QD metformin 55.3  7.9  169.8  
Stenlof, 201318 387 26 Canagliflozin 100 mg QD none 55.4  8.1  170.1  
Stenlof, 201318 389 26 Canagliflozin 300 mg QD none 55.5  8.0  170.1  
Forst, 201419 228 26 Canagliflozin 100 mg QD pioglitazone and metformin 57.5  8.0  166.5  
Forst, 201419 229 26 Canagliflozin 300 mg QD pioglitazone and metformin 57.7  8.0  163.8  
Inagaki, 201420 183 24 Canagliflozin 100 mg QD none 58.3  8.0  160.4  
Inagaki, 201420 182 24 Canagliflozin 200 mg QD none 57.8  8.0  164.1  
Qiu, 201421 186 18 Canagliflozin 50 mg BID metformin 57.8  7.7  162.0  
Qiu, 201421 186 18 Canagliflozin 150 mg 
BID 
metformin 56.9  7.7  162.9  
Ji, 201522_1a 449 18 Canagliflozin 100 mg QD metformin (with or without 
sulfonylurea) 
56.1  7.9  157.5  
Ji, 201522_1a 453 18 Canagliflozin 300 mg QD metformin (with or without 
sulfonylurea) 
56.1  8.0  159.3  
Ji, 201522_2b 218 18 Canagliflozin 100 mg QD metformin 54.7  7.9  158.4  
Ji, 201522_2b 222 18 Canagliflozin 300 mg QD metformin 55.3  8.0  158.4  
Ji, 201522_3c 231 18 Canagliflozin 100 mg QD sulfonylurea and metformin 57.6  7.9  155.7  
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Source 
Number of 
participant
s 
Treatment 
duration 
(weeks) 
SGLT-2 inhibitors background antidiabetic therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
BL FPG 
(mg/dl) 
Ji, 201522_3c 231 18 Canagliflozin 300 mg QD sulfonylurea and metformin 57.0  8.0  160.2  
Haring, 201323 450 24 Empagliflozin 10 mg QD sulfonylurea and metformin 57.0  8.1  151.2  
Haring, 201323 441 24 Empagliflozin 25 mg QD sulfonylurea and metformin 57.1  8.1  153.9  
Roden, 201324 452 24 Empagliflozin 10 mg QD none 55.5  7.9  153.6  
Roden, 201324 452 24 Empagliflozin 25 mg QD none 54.4  7.9  153.5  
Rosenstock, 201325 142 12 Empagliflozin 10 mg QD metformin 59.5  8.0  173.5  
Rosenstock, 201325 141 12 Empagliflozin 25 mg QD metformin 59.5  8.0  177.0  
Ferrannini, 201326 163 12 Empagliflozin 10 mg QD none 57.8  7.9  174.6  
Ferrannini, 201326 164 12 Empagliflozin 25 mg QD none 57.0  7.8  171.0  
Kovacs, 201427 330 24 Empagliflozin 10 mg QD pioglitazone (with or without 
metformin) 
54.7  8.2  151.8  
Kovacs, 201427 333 24 Empagliflozin 25 mg QD pioglitazone (with or without 
metformin) 
54.4  8.2  151.7  
Haring, 201428 424 24 Empagliflozin 10 mg QD metformin 55.7  7.9  155.1  
Haring, 201428 421 24 Empagliflozin 25 mg QD metformin 55.8  7.9  152.5  
Kadowaki, 201429 218 12 Empagliflozin 10 mg QD none 58.3  7.9  156.6  
Kadowaki, 201429 218 12 Empagliflozin 25 mg QD none 58.0  8.0  156.2  
Ross, 201530 322 16 Empagliflozin 12.5 mg 
BID 
metformin 57.7  7.8  157.8  
Ross, 201530 321 16 Empagliflozin 25 mg QD metformin 58.1  7.7  159.0  
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Source 
Number of 
participant
s 
Treatment 
duration 
(weeks) 
SGLT-2 inhibitors background antidiabetic therapy 
Age  
(years) 
Baseline 
HbA1c 
 (%) 
BL FPG 
(mg/dl) 
Ross, 201530 322 16 Empagliflozin 5 mg BID metformin 58.5  7.8  161.4  
Ross, 201530 321 16 Empagliflozin 10 mg QD metformin 58.3  7.8  161.4  
Roden, 201531 452 76 Empagliflozin 10 mg QD none 55.5  7.9  153.9  
Roden, 201531 452 76 Empagliflozin 25 mg QD none 54.4  7.9  153.9  
Haering, 201532 450 76 Empagliflozin 10 mg QD sulfonylurea and metformin 57.0  8.1  151.2  
Haering, 201532 441 76 Empagliflozin 25 mg QD sulfonylurea and metformin 57.1  8.1  153.9  
NCT0128999033_1a 424 76 Empagliflozin 10 mg QD metformin 55.7  7.9  155.1  
NCT0128999033_1a 421 76 Empagliflozin 25 mg QD metformin 55.8  7.9  152.5  
NCT0128999033_2b 331 76 Empagliflozin 10 mg QD pioglitazon 55.0  NR NR 
NCT0128999033_2b 334 76 Empagliflozin 25 mg QD pioglitazon 55.1  NR NR 
QD once-daily dosing, BID twice-daily dosing, NR not reported 
a 1 represents the first pair of the article 
b 2 represents the second pair of the article 
c 3 represents the third pair of the article 
 
 
 
 
 
 
36 
 
Table 5 Three classifications for studies 
Type A Study in non-Asian subjects 
 19 studies 
Study in Asian subjects 
11 studies 
 
Type B Study in non-Asian subjects 
20 studies 
Study in Asian subjects (excluding the 
Japanese) 
6 studies 
Study in Japanese subjects a 
5 studies 
Type C Study conducted multinationally 
24 studies 
Study conducted in Asia 
(excluding Japan) 
2 studies 
Study conducted in Japan a 
5 studies 
a Studies classified as "Study in Japanese subjects" (Type B) and "Study conducted in Japan" (Type C) were the same. 
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 3.3.2. Quality of included studies and publication bias 
 The Jaded score was 3.90, and we determined the quality of included studies 
was high. The funnel plot of WMD for HbA1c and standard error in 30 studies is shown 
in Fig. 4. Funnel plot asymmetry was assessed using Egger's test and it indicated that 
there was no publication bias (p = 0.117). The I2 statistic test for heterogeneity was 
76.2%, and the value of Q statistic was significant. 
 
  
Figure 4 Funnel plot of weighted mean difference for HbA1c and standard error 
 
3.3.3. Primary outcome 
 HbA1c data for 75 arms from 30 studies were pooled. The difference of HbA1c 
between the SGLT-2 inhibitor group and placebo group was −0.657% (95% CI −0.696 
to −0.617). 
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3.3.4. Univariate meta-regression 
 Univariate meta-regression showed relations between the WMD in the change 
of HbA1c from baseline value and several factors such as study design 
(coefficient=0.201, p<0.001), percentage of male (−0.009, p <0.001), baseline HbA1c 
values (−0.087, p = 0.162), baseline fasting plasma glucose (−0.006, p = 0.020), BMI 
(0.015, p = 0.081), body weight (0.003, p = 0.180) and percentage of Asians (−0.001, p 
= 0.011). Additionally, studies in Asian subjects in Type A (−0.103, p = 0.016), studies 
in Japanese subjects in Type B (−0.200, p = 0.001), and studies conducted in Japan in 
Type C (−0.178, p =0.002) showed relations in each of the analyses. Because BMI and 
body weight correlated with the percentage of Asians, we excluded BMI and body 
weight from the multivariate meta-regression, and used the three classifications (Type A, 
B and C). Furthermore, study design correlated with the three classifications, we 
exclude study design from multivariate meta-regression. 
 
3.3.5. Multivariate meta-regression 
 The factors significantly associated with the WMD in the change of HbA1c 
from baseline using univariate meta-regression were further analyzed by multivariate 
meta-regression (Table 6). Baseline fasting plasma glucose was identified as a common 
influencing factor in all the analyses using the three types of classifications. Also, 
percentage of male in Type A, and percentage of male and baseline HbA1c were 
identified as influencing factors, respectively. 
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Table 6 Results of multivariate meta-regression analysis 
 
3.4. Discussion 
 We performed meta-regression analyses to identify the factors influencing the 
glucose-lowering efficacy of SGLT-2 inhibitors by analyzing 30 studies with 75 arms 
Factors Estimate 95% CI P-value 
a. Multivariate meta-regression with Type A 
Male (%) -0.007 (-0.012, -0.002) 0.008 
Baseline HbA1c (%) -0.111 (-0.357, 0.136) 0.378 
Baseline fasting plasma glucose 
(mg/dl) 
-0.009 (-0.015, -0.003) 0.003 
Study in Asian subjects -0.097 (-0.200, 0.006) 0.066 
b.  Multivariate meta-regression with Type B 
Male (%) -0.005 (-0.011, 0.002) 0.142 
Baseline HbA1c (%) -0.138 (-0.394, 0.118) 0.292 
Baseline fasting plasma glucose 
(mg/dl) 
-0.009 (-0.015, -0.003) 0.005 
Study in Asian subjects -0.086 (-0.193, 0.021) 0.114 
Study in Japanese subjects -0.149 (-0.315, 0.016) 0.077 
c.  Multivariate meta-regression with Type C 
Male (%) -0.007 (-0.014, 0.000) 0.036 
Baseline HbA1c (%) -0.237 (-0.470, -0.004) 0.046 
Baseline fasting plasma glucose 
(mg/dl) 
-0.006 (-0.011, -0.001) 0.029 
Study conducted in Asia 0.070 (-0.044, 0.185) 0.227 
Study conducted in Japan -0.063 (-0.222, 0.096) 0.435 
Type A, the studies were divided into 2 groups; a “study in Asian subjects” or a “study in non-Asian 
subjects” 
Type B, the studies were divided into 3 groups; a “study in Asian subjects”, a “study in Japanese subjects” 
or a “study in non-Asian subjects.” 
Type C, the studies were divided into three groups: a “study conducted in Asia”, a “study conducted in 
Japan” or a “study conducted multinationally.”  
HbA1c hemoglobin A1c 
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and 20,170 patients. We found WMD in the placebo-adjusted change of HbA1c from 
baseline was −0.66 %, which is consistent with the previously reported meta-analyses 
ranging between −0.455% and −0.78%. 
 Using univariate meta-regression, factors such as percentage of male, baseline 
HbA1c values, baseline fasting plasma glucose, BMI, body weight and percentage of 
Asians were identified to be correlated with WMD in the change of HbA1c from 
baseline. The results of baseline HbA1c values, baseline fasting plasma glucose and 
BMI were in agreement with the analysis conducted by Monami et al. [27]. Additionally, 
in the present study, relations were shown in studies in Asian subjects in the 
classification Type A, studies in Japanese subjects in Type B and studies conducted in 
Japan in Type C. Based on these results, SGLT-2 inhibitors exhibit a better 
glucose-lowering efficacy with higher baseline HbA1c, higher fasting glucose, with 
lower BMI and body weight, and with a higher percentage of Asians. A better glucose 
lowering efficacy was also shown in studies in Asian subjects, studies in Japanese 
subjects and studies conducted in Japan. 
 Multivariate meta-regression showed a better glucose lowering efficacy with 
high baseline fasting plasma glucose, suggesting baseline fasting plasma glucose is a 
robust factor. Additional categorizations regarding ethnicity of study subjects and study 
regions were not identified as an influencing factor of glucose-lowering efficacy of 
SGLT-2 inhibitors. 
 Ferrannini et al. [28] concluded SGLT-2 inhibitor induced glycosuria could be 
described as a dual function of the glomerular filtration rate (GFR) and plasma glucose 
levels with a coefficient of determination of 65% (or a multiple r =0.74) . This may 
explain our findings that higher baseline fasting plasma glucose is a factor of greater 
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efficacy of SGLT-2 inhibitors on WMD in the change of HbA1c from baseline. Because 
GFR was assessed in a few clinical studies, we did not include GFR as a pre-specified 
factor. Our finding suggests that paying attention to baseline fasting plasma glucose in 
planning and conducting of clinical studies, and in comparing the data with other 
studies is important. 
 We used three classifications regarding ethnicity of study subjects and study 
regions to explore potential differences among them. In the classification Type A, Japan 
was included in Asia. In Type B and C, we distinguished between Asia and Japan 
focusing on ethnicity in Type B and on regions in Type C. Any factors of these 
classifications were not identified as an influencing factor of glucose-lowering efficacy 
of SGLT-2 inhibitors. Our finding indicates that differences in the contribution of the 
insulin secretory defect and insulin resistance in the pathophysiology of type 2 diabetes 
between Asians and non-Asians do not affect the response to SGLT-2 inhibitors. The 
reason could be explained by its insulin independent mechanism of action, neither 
insulin secretion nor sensitization. 
 Our analysis indicates that the baseline fasting plasma glucose is associated 
with the efficacy of SGLT-2 inhibitors. This result should be taken into account when 
planning and conducting clinical studies, and comparing the data with other clinical 
studies. 
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4. Research 3 (Placebo effect) 
4.1. Objectives 
 Through our research 1 and 2, different placebo phenomenon was observed 
among study regions. For example, high placebo responses were observed in study 
conducted in Asia and low placebo responses were observed in study conducted in 
Japan. This placebo phenomenon showed same trend in both the DPP -4 inhibitor and 
the SGLT-2 inhibitor studies. 
 The placebo phenomenon in chronic pain or neuropsychiatric disorder has been 
widely recognized in clinical research because high placebo responses were reported to 
be the cause of failure of clinical studies. In type 2 diabetes area, however, placebo 
effect has rarely been discussed. 
 Thus, we conducted meta-regression analyses to assess the factors that 
contributing to placebo effect in clinical studies for both DPP-4 inhibitor and SGLT-2 
inhibitor. Potential factors including ethnicity of study subjects and study regions; in 
particular, Japanese were dealt separately from other Asians. 
 
4.2. Method 
4.2.1. Data sources, searches and extraction 
 We used the eligible studies identified in research 1 and research 2. The 
primary outcome was HbA1c change from baseline in placebo group at each study’s 
primary endpoint. 
 In order to further explore potential differences in HbA1c change from baseline 
in placebo group among the ethnicity and study regions, we used two classifications, 
Type B and C, described in method of research 1 and research 2. 
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 4.2.2. Statistical analysis 
 Meta-regression was applied to investigate potential factors affecting the 
HbA1c change from baseline in placebo group of each DPP-4 inhibitor and SGLT-2 
inhibitor study. The pre-specified factors such as study duration, percentage of male, age, 
duration of diabetes, baseline HbA1c values, fasting plasma glucose, BMI, body weight, 
percentage of Asians and additional categorizations regarding ethnicity of study subjects 
and study regions were used in the meta-regression. 
 Same method was applied for univariate and multivariate meta-regression 
analyses as in research 1 and 2. Analyses were performed using StatDirect version 2.7.9 
(StatDirect Ltd., Altrincham, Cheshire, UK) and R software, version 3.2.0 [23]. 
 
4.3. Result 
4.3.1. Literature search 
DPP-4 inhibitor study 
 A total of 79 studies (Appendix 1; reference 1-79) with 86 arms and 10,561 
patients were used for the analysis (Table 1). Regarding the factors related to ethnicity 
and regions, in Type B, 17 were studies in Asian subjects, 18 were studies in Japanese 
subjects and 41 were studies in non-Asian subjects. As for Type C, 6 were studies 
conducted in Asia, 18 were studies conducted in Japan and 55 were studies conducted 
multinationally (Table 2). 
 
SGLT-2 inhibitor study 
 A total of 30 studies (Appendix 2: 1-33) with 38 arms and 4,904 patients were 
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used for the analysis (Table 4). Regarding the factors related to ethnicity and regions, in 
Type B, 6 were studies in Asian subjects, 5 were studies in Japanese subjects and 20 
were studies in non-Asian subjects. As for Type C, 2 were studies conducted in Asia, 5 
were studies conducted in Japan and 24 were studies conducted multinationally (Table 
5). 
 
4.3.2. Univariate meta-regression 
DPP-4 inhibitor study 
 Univariate meta-regression showed relations between the HbA1c change from 
baseline in placebo group and several factors such as study design (coefficient=-0.112, p 
= 0.030), study duration (−0.007, p = 0.052), percentage of male (0.007, p =0.007), age 
(0.031, p <0.001), duration of diabetes (0.031, p =0.015), BMI (−0.012, p =0.174) and 
body weight (−0.005, p =0.173). Additionally, studies in Japanese subjects (0.198, p 
<0.001) and studies in Asian subjects (−0.173, p =0.002) in Type B, and studies 
conducted in Japan (0.228, p <0.001) and studies conducted in Asia (−0.259, p =0.001) 
in Type C showed relations in each of the analyses. Because BMI and body weight 
correlated with the percentage of Asians, we excluded BMI and body weight from the 
multivariate meta-regression, and used the two classifications (Type B and C). 
 
SGLT-2 inhibitor study 
 Univariate meta-regression showed relations between the HbA1c change from 
baseline in placebo group and several factors such as study design (coefficient=−0.119, 
p = 0.001), percentage of male (0.008, p =0.024), age (0.025, p =0.051) and percentage 
of Asians (0.001, p =0.163). Additionally, studies in Japanese subjects in Type B (0.316, 
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p <0.001), and studies conducted in Japan (0.292, p <0.001) and studies conducted in 
Asia (−0.299, p =0.001) in Type C showed relations in each of the analyses. 
 
4.3.3. Multivariate meta-regression 
DPP-4 inhibitor study 
 The factors significantly associated with the HbA1c change from baseline in 
placebo group using univariate meta-regression were further analyzed by multivariate 
meta-regression (Table 7). Study design and duration of diabetes were identified as a 
common influencing factor in the both analyses using the two types of classifications. 
Also, study in Asian subjects in Type B and study conducted in Asia in Type C were 
identified as influencing factors. 
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Table 7 Results of multivariate meta-regression analysis (DPP-4 inhibitor study) 
 
SGLT-2 inhibitor study 
 The factors significantly associated with the HbA1c change from baseline in 
placebo group using univariate meta-regression were further analyzed by multivariate 
meta-regression (Table 8). Study design was identified as a common influencing factor 
in the both analyses using the two types of classifications. Also, age with type B and 
study conducted in Asia in Type C was identified as influencing factors. 
Factors Estimate 95% CI P-value 
a.  Multivariate meta-regression with Type B 
Study design (mono/combination) -0.192 (-0.356, -0.027) 0.022 
Study duration (week) -0.004 (-0.018, 0.010) 0.571 
Male (%) 0.001 (-0.007, 0.009) 0.820 
Age (years) -0.005 (-0.028, 0.018) 0.643 
Duration of diabetes (years) 0.046 (0.003, 0.089) 0.036 
Study in Asian subjects -0.185 (-0.336, -0.034) 0.017 
Study in Japanese subjects 0.104 (-0.078, 0.286) 0.261 
b.  Multivariate meta-regression with Type C 
Study design (mono/combination) -0.202 (-0.362, -0.043) 0.013 
Study duration (week) -0.004 (-0.018, 0.009) 0.542 
Male (%) 0.001 (-0.007, 0.009) 0.834 
Age (years) -0.002 (-0.025, 0.020) 0.845 
Duration of diabetes (years) 0.049 (0.007, 0.091) 0.021 
Study conducted in Asia -0.235 (-0.414, -0.056) 0.010 
Study conducted in Japan 0.099 (-0.082, -0.279) 0.284 
Type B, the studies were divided into 3 groups; a “study in Asian subjects”, a “study in Japanese subjects” 
or a “study in non-Asian subjects.” 
Type C, the studies were divided into three groups: a “study conducted in Asia”, a “study conducted in 
Japan” or a “study conducted multinationally.”  
HbA1c hemoglobin A1c 
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Table 8 Results of multivariate meta-regression analysis (SGLT-2 inhibitor study) 
 
4.4. Discussion 
 In the present study, we conducted analysis of placebo effect in clinical studies 
for DPP-4 inhibitors and SGLT-2 inhibitors. Multivariate meta-regression showed a 
larger HbA1c change from baseline in placebo group in the studies conducted in Asia 
for the both analyses, suggesting studies conducted in Asia is a robust factor. In other 
words, larger placebo response, improvement in the placebo group, was shown in 
studies conducted in Asia. This result was in agreement with what we found in our 
research 1 and 2. 
 He et al. [29] conducted meta-analysis and reported that HbA1c in the placebo 
arm declined by 0.26 % in the studies of DPP-4 inhibitors conducted in patients with 
Factors Estimate 95% CI P-value 
a.  Multivariate meta-regression with Type B 
Study design (mono/combination) -0.236 (-0.380, -0.092) 0.001 
Male (%) 0.000 (-0.009, 0.008) 0.923 
Age 0.035 (0.007, 0.062) 0.013 
Study in Asian subjects 0.000 (-0.128, 0.128) 0.998 
Study in Japanese subjects 0.083 (-0.192, 0.358) 0.553 
b.  Multivariate meta-regression with Type C 
Study design (mono/combination) -0.211 (-0.339, -0.083) 0.001 
Male (%) 0.003 (-0.005, 0.012) 0.435 
Age 0.025 (0.000, 0.050) 0.052 
Study conducted in Asia -0.262 (-0.048, -0.076) 0.006 
Study conducted in Japan 0.032 (-0.213, 0.276) 0.798 
Type B, the studies were divided into 3 groups; a “study in Asian subjects”, a “study in Japanese subjects” 
or a “study in non-Asian subjects.” 
Type C, the studies were divided into three groups: a “study conducted in Asia”, a “study conducted in 
Japan” or a “study conducted multinationally.”  
HbA1c hemoglobin A1c 
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type 2 diabetes in China, whereas the placebo effect of those conducted outside China 
was close to 0. The authors concluded that there were significant differences in response 
in the placebo group of DPP-4 studies conducted in China and those conducted outside 
of China. In our research, China was the main region in the studies in Asia. Our findings 
were in agreement with those by He et al. [29], not only for DPP-4 studies but also for 
SGLT-2 studies, and supported their consideration of the reason for a large placebo 
effect; the significant benefit to participate in clinical study for subjects in China, 
obtaining more resource of medical care, could cause a bias and obvious impact on 
management of diabetes, and thus cause better blood glucose control even in placebo 
arm in China. 
 Although there was no statistical difference, coefficients of studies in Japanese 
subjects in Type B and studies conducted in Japan in Type C were positive and had the 
least influence on placebo effect. This is thought to be due to the adequate management 
in the medical practice in Japan, which causes less impact on placebo arm. 
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5. Overall Discussion 
 In order to discuss the points to be considered in future clinical development of 
oral hypoglycemic drug, three types of research were conducted. 
 The finding of the first research suggested that a higher baseline HbA1c is a 
factor of greater efficacy of DPP-4 inhibitors on WMD in the change of HbA1c from 
baseline. A higher baseline HbA1c has been reported to be a predictor of a greater 
HbA1c reduction with the use of DPP-4 inhibitors [20, 25]. However, the HbA1c value 
used by Esposito et al. [20] and Deacon [25] in their analysis was different from our 
study; they used absolute HbA1c reduction without taking into account the placebo 
effect. We used the WMD in the change of HbA1c in multivariate meta-regression and 
the analysis showed a better glucose lowering efficacy with high baseline HbA1c, 
suggesting baseline HbA1c is a robust factor. 
 Second, studies in Japanese subjects and studies conducted in Japan are factors 
affecting the efficacy of DPP-4 inhibitors. However, studies in Asian subjects and 
studies conducted in Asia are not associated, which means the efficacy of DPP-4 
inhibitors shows no apparent difference between studies in Asian subjects and studies in 
non-Asian subject, or studies conducted in Asian and studies conducted multinationally. 
This finding differs from those by Kim et al. [15], who reported that the DPP-4 
inhibitors exhibit a better glucose-lowering efficacy in Asians than in other ethnic 
groups. Our finding indicates that differences in the contribution of the insulin secretory 
defect and the insulin resistance in the pathophysiology of type 2 diabetes between 
Asians and non-Asians do not significantly affect the response to DPP-4 inhibitors and 
it does not explain the mechanism underlying the difference in the response. 
 The finding of the second research suggested that a higher baseline fasting 
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plasma glucose is a factor of greater efficacy of SGLT-2 inhibitors on WMD in the 
change of HbA1c from baseline. It was based on the multivariate meta-regression, 
suggesting baseline fasting plasma glucose is a robust factor. This finding is in 
agreement of the research by Monami et al. [27], though they employed a univariate 
meta-regression analysis. Our findings may be explained by the fact that glycosuria and 
plasma glucose levels have a strong positive correlation. 
 We used three classifications regarding ethnicity of study subjects and study 
regions to explore potential differences among them. However, no factors of these 
classifications were identified as an influencing factor of glucose-lowering efficacy of 
SGLT-2 inhibitors. Our finding indicates that differences in the contribution of the 
insulin secretory defect and the insulin resistance in the pathophysiology of type 2 
diabetes between Asians and non-Asians does not affect the response to SGLT-2 
inhibitors. The reason could be explain by its insulin independent mechanism of action, 
neither insulin secretion nor sensitization. 
 The finding of the third research suggested that studies conducted in Asia is a 
factor of larger HbA1c change from baseline in the placebo group. He et al. [29] 
reported that there were significant differences in response in the placebo group 
between DPP-4 studies conducted in China and those conducted outside of China. In 
our research, China was the main region in studies conducted in Asia. Given that our 
findings were in agreement with those by He et al. [29], not only for DPP-4 studies but 
also for SGLT-2 studies and supported their consideration of the reason for this high 
placebo effect; the significant benefit to participate in clinical study for subjects in 
China, obtaining more resource of medical care, could cause a bias and obvious impact 
on management of diabetes, and thus cause better blood glucose control even in placebo 
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arm in China. 
 Publication bias may exist and have imposed some limitations on our study. 
Another limitation is that we used summary data and not individual patient-level data. 
Furthermore, we included South Asians in the studies in Asian subjects, which mainly 
consisted of East Asians, because it was not possible to distinguish in some studies 
whether Asians included South Asians or not. The Asian population is also ethnically 
heterogeneous and has different demographic characteristics [30]. 
 
6. Conclusion 
 Paying attention to baseline HbA1c for DPP-4 inhibitors and baseline fasting 
plasma glucose for SGLT-2 inhibitors in planning and conducting clinical studies, and in 
comparing the data with other clinical studies is important. With regards to the ethnicity 
of study subjects, our finding indicates that differences in the contribution of the insulin 
secretory defect and the insulin resistance in the pathophysiology of type 2 diabetes 
between Asians and non-Asians do not affect the response to active oral hypoglycemic 
agents which have insulin independent mechanism. On the other hand, placebo effect 
was shown to be different among the subject ethnicity and/or study region. This 
differential HbA1c response in the placebo arm should be taken into consideration when 
comparing the data based on different clinical practice in each region. In the future, it is 
desirable to evaluate the influence of different study regions and/or subject ethnicity on 
efficacy and safety in multiregional studies.
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